Prognostic significance of soluble Fas in the serum of patients with bladder cancer
Prognostic significance of soluble Fas in the serum of patients with bladder cancer
复制标题
DOI：
10.1016/s0022-5347(01)62960-4
复制
发表时间：
1998-08-01
影响因子：
6.6
通讯作者：
Bonavida, B
中科院分区：
文献类型：
--
作者：
Mizutani, Y;Yoshida, O;Bonavida, B
目的：Fas抗原(Fas)和Fas配体的相互作用在细胞毒T淋巴细胞和自然杀伤细胞介导的肿瘤细胞杀伤中起重要作用。循环中的可溶性Fas(SFas)拮抗细胞表面Fas功能，可能干扰对自身肿瘤的免疫监视。材料与方法：采用酶联免疫吸附试验检测173例膀胱癌患者血清中sFas的水平。用四唑蓝染色法检测抗Fas单抗的细胞毒作用。结果：膀胱癌患者血清中sFas的平均水平是正常人的3倍。根据血清sFas水平将患者分为2组。血清sFas水平低(<平均值)的膀胱癌患者的疾病特异性生存率高于血清sFas水平高(大于平均值)的患者。血清sFas水平高低的膀胱癌患者在年龄、性别、组织学分期、分级等方面均无统计学差异。此外，在5年随访中，血清sFas水平低的Ta膀胱癌患者的术后无瘤间隔时间比血清sFas水平高的患者长。检测了25例患者外周血淋巴细胞对自体肿瘤细胞的杀伤活性。血清sFas水平与抗自身肿瘤细胞毒作用呈负相关。结论：血清sFas水平升高可能与膀胱癌患者预后不良有关。
Purpose: The interaction of Fas antigen (Fas) and Fas ligand plays an important role in cytotoxic T lymphocyte- and natural killer cell-mediated cytotoxicity against cancer cells. Circulating soluble Fas (sFas) antagonizes cell-surface Fas function and may interfere with immune surveillance against autologous tumors. This possibility was examined in patients with bladder cancer.Materials and Methods: The levels of sFas in the serum of 173 patients with bladder cancer were determined by using an enzyme-linked immunosorbent assay. Cytotoxicity of anti-Fas monoclonal antibody was examined by a 1-day microculture tetrazolium dye assay. Anti-autologous tumor cytotoxic activity was determined by the 12-hour Cr-51 release assay.Results: The mean serum level of sFas in patients with bladder cancer was threefold higher than the mean in normal donors. The patients were divided into 2 groups based on the level of sFas in the serum. Bladder cancer patients with low level of serum sFas (less than the mean value) had a higher disease-specific survival rate, when compared with those with high level of serum sFas (greater than the mean value) in the 5-year followup. There were no statistical differences in patients' age and sex, as well as histological stage and grade of bladder cancer between the patients with high and low levels of serum sFas. Furthermore, patients with Ta bladder cancer with a low level of serum sFas had a longer postoperative tumor-free interval than those with high level in the 5-year followup. Cytotoxic activity of peripheral blood lymphocytes against autologous tumor cells was examined in 25 patients. There was an inverse correlation between the level of serum sFas and anti-autologous tumor cytotoxicity.Conclusions: The findings suggest that elevated levels of sFas in the serum might be associated with poor prognosis in patients with bladder cancer.